Psychedelic Stocks

Washington State Lawmakers Allocate $200K to Psilocybin Research

Last week, legislators in Washington State advanced a budget measure to the state’s governor. This measure includes a proposal to allocate $200,000 in funding to be used to support the Psilocybin Wellness Workgroup to study the possible legalization of psilocybin services in the state.

If the bill is approved by Gov. Jay Inslee, the workgroup will be tasked with compiling a report on psilocybin services opportunities and wellness as stated in the 2023 fiscal year budget proposal. Most of the focus on the psilocybin section will center on analysis and potential improvements that can be made to a Senate measure, which was stalled.

This measure, SB 5660, would have allowed individuals aged 21 and above to consume products that contain psilocin and psilocybin in the presence of a state-licensed, trained psilocybin service administrator. It would have also legalized supported psilocybin experiences.

The group will also assess the current systems in place in the state that monitor the manufacture, tracking and testing of marijuana in an effort to determine adaptations required for their use with psilocybin as well as their suitability. This is in addition to making recommendations that would ensure that there was equitable access to a legal psilocybin industry.

This news comes after activists in the state filed a proposal for the November ballot that would legalize the use of psilocybin under the support of trained facilitators.

Psychedelic Medicine Alliance Washington, an advocacy group, applauded the inclusion of this funding in the budget, with Kody Zalewski, the group’s codirector, stating in a press release that the group was pleased that the state legislature in Washington had listened to their constituents by financing the budget through these provisions.

Commit to Change WA, another advocacy group in the state, is also backing another proposed initiative for the November ballot that would decriminalize the possession of small amounts of all drugs and support expanded long-term recovery and outreach services for individuals suffering from drug-use disorders. The state of Oregon approved a similar measure to decriminalize all drugs in November 2020.

In other news, the state’s Supreme Court overturned the felony law against drug possession in the state completely, which prompted legislators to reduce the felony charge for drug possession in Washington state to a misdemeanor.

Additionally, the city of Seattle recently became the biggest city in the country to decriminalize psychedelics, after the city council of Seattle passed a resolution to do so in October 2021.

The research and development work being done by companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) has also partially played a role in educating the public about the therapeutic potential of psychedelics. It is not surprising, therefore, that the wave demanding policy reform has come when many of these companies have made headway in their research.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Pursues Dual Pathway for Preservative-Free Ketamine-Based Therapies

The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…

2 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Gains FDA Nod for Preservative-Free Ketamine Suitability Petition

FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Secures FDA Fast Track for IV Ketamine Formulation NRX-100 in Suicidal Depression

The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

4 months ago